儿童细小病毒B19相关急性心肌炎的临床谱系
PVB19阳性病例中87.9%集中于2024年,且19.7%发生死亡、心脏移植或持久左心室辅助装置植入,显著高于PVB19阴性组的1.2%。
要点
- 2024年意大利儿童PVB19阳性急性心肌炎病例激增,主要影响≤7岁儿童。
- PVB19阳性急性心肌炎不良结局(死亡/移植/持久LVAD)发生率为19.7%,显著高于阴性组。
核心结论
- 2024年意大利暴发期间儿童PVB19阳性急性心肌炎病例激增,并与严重不良结局相关。
- 诊断需高度怀疑并早期进行病毒学检测,以指导管理并可能改善预后。
研究设计与样本
- 共217例,其中66例血浆PVB19 DNA阳性(PVB19+),82例PVB19检测阴性作为对照组(PVB19-)。
- 同时评估2004年至2024年伦巴第地区儿童心肌炎的群体发病率趋势。
主要发现
- PVB19+急性心肌炎中58/66(87.9%)于2024年入院,中位年龄32个月,51/66(77.2%)≤7岁,36/66(54.5%)为男孩。
- 26/66(39.4%)有组织学资料,其中23例(88.4%)为淋巴细胞性心肌炎,84.0%心肌标本检出PVB19 DNA。
- 25/65(38.4%)接受基因检测,均未发现致病或可能致病变异。
- PVB19+组13/66(19.7%)发生死亡、心脏移植或持久LVAD(6例死亡、5例持久LVAD、5例移植),PVB19-组1/82(1.2%)发生持久LVAD后移植(P<0.001)。
临床怎么用
- 对儿童急性心肌炎应高度怀疑PVB19感染,尤其在暴发期间及≤7岁儿童中。
- 早期进行病毒学检测(血浆PVB19 DNA)有助于明确诊断并指导管理。
局限性
- 回顾性观察设计。
- 部分病例缺乏组织学和基因检测数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Parvovirus B19 is a DNA virus transmitted via respiratory droplets, commonly causing erythema infectiosum in children but also implicated in acute myocarditis. In 2024, an outbreak of parvovirus B19 infections was reported across Europe and the United States. Despite growing awareness, data on the clinical features and outcomes of children with parvovirus B19-associated acute myocarditis remain limited. METHODS: This multicenter retrospective observational study reviewed medical records of pediatric patients (<18 years of age) admitted with acute myocarditis to 11 Italian tertiary pediatric cardiac centers between January 1, 2022, and October 31, 2024. Of 217 cases, 66 had confirmed parvovirus B19 DNA in plasma (PVB19+), whereas 82 with negative parvovirus B19 testing served as a comparator group (PVB19-). Population-based incidence trends of pediatric myocarditis were also evaluated in the Lombardy region from 2004 through 2024. RESULTS: Among PVB19+ acute myocarditis cases, 58 of 66 (87.9%) were admitted in 2024. The median age was 32 months, with 51 of 66 (77.2%) ≤7 years of age, and 36 of 66 (54.5%) were boys. Median plasma viral load was 34 411 copies/mL, whereas only 30 of 56 (53.6%) had immunoglobulin M (IgM) positivity. Among 26 of 66 (39.4%) with available histology, 23 (88.4%) had lymphocytic myocarditis, and parvovirus B19 DNA was identified in 84.0% of myocardial specimens. Among 25 of 65 (38.4%) who underwent genetic testing, none had pathogenic or likely pathogenic variants. Overall, 13 of 66 (19.7%) died, underwent heart transplantation, or received a durable left ventricular assist device (in total, there were 6 deaths, 5 durable left ventricular assist devices, and 5 transplantations) compared with 1 of 82 (1.2%) among PVB19- acute myocarditis (one patient who received a durable left ventricular assist device and later underwent transplantation; P<0.001). A marked increase in regional and institutional myocarditis incidence in pediatric acute myocarditis was observed in 2024, predominantly in children ≤7 years of age, driven by PVB19+ cases. CONCLUSIONS: During the 2024 parvovirus B19 outbreak, pediatric PVB19+ acute myocarditis cases surged in Italy and were associated with severe outcomes. A high index of suspicion is required for diagnosis, and early virological testing is essential to guide management and potentially improve outcomes.
引用
- Ammirati E, Veronese G, Raimondi F, et al. Clinical Spectrum of Children With Parvovirus B19-Associated Acute Myocarditis. Circulation. 2026. PMID: 41487093. doi:10.1161/CIRCULATIONAHA.125.075943
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。